Dr. Keith Flaherty is the director of the Henri and Belinda Termeer Center for Targeted Therapies. Dr. Flaherty and his exceptional team of clinicians and scientists are spearheading research into promising new treatment options for patients through phase I clinical investigation.
Three projects led by MGH investigators were named among the Clinical Research Forum’s Top 10 Clinical Research Achievements of 2012 at the organization’s annual meeting on April 18.
Use of an experimental targeted drug to treat metastatic melanoma tumors with a specific genetic signature was successful in more than 80 percent of patients in a phase 1 clinical trial.
New research by a team from the Broad Institute, Dana-Farber Cancer Institute, and Massachusetts General Hospital suggests that how cancer evade drug treatment may depend on the interplay between tumor cells and their healthy counterparts.
Combined treatment with two drugs targeting different points in the same growth-factor pathway delayed the development of treatment resistance in patients with BRAF-positive metastatic malignant melanoma.
Three projects led by Massachusetts General Hospital (MGH) investigators have been named among the Clinical Research Forum's Top 10 Clinical Research Achievements of 2012.